Wegovy prescribing information revised in June 2026 with two contraindications

Wegovy (semaglutide) has a prescribing information document revised as of June 2026 that carries two contraindications, 11 warnings and precautions, and specific instructions covering pregnancy, breastfeeding and pediatric use ^[1].

The two contraindications are a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), and a known hypersensitivity to semaglutide or any of the product's inactive ingredients ^[1]. The boxed warning about thyroid C-cell tumors remains: semaglutide caused such tumors in rodents at clinically relevant exposures, and the label states it is unknown whether Wegovy causes thyroid C-cell tumors, including MTC, in humans ^[1].

One of the 11 warnings covers pulmonary aspiration during general anesthesia or deep sedation. The label says aspiration has been reported in patients receiving GLP-1 receptor agonists who were undergoing elective surgeries or procedures, and it instructs patients to inform healthcare providers of any planned surgeries or procedures ^[1]. The remaining warnings address acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, risk of thyroid C-cell tumors, and sharing the Wegovy FlexTouch pen between patients ^[1].

On pregnancy, the label states that Wegovy may cause fetal harm. For patients receiving it for cardiovascular risk reduction or weight reduction, or for MASH where the potential risk outweighs the potential benefit, the label directs discontinuation at least two months before a planned pregnancy because of the long half-life of semaglutide ^[1]. On lactation, it states that breastfeeding is not recommended during treatment with Wegovy tablets ^[1].

Wegovy injection is indicated for adults and for pediatric patients aged 12 years and older with obesity, and the full prescribing information includes a pediatric weight reduction and long-term maintenance study in that age group ^[1]. The label's Recent Major Changes table lists only one item dated 06/2026: the warning not to share the Wegovy FlexTouch pen between patients, even if the needle is changed. It also notes that the Suicidal Behavior and Ideation warning was removed in January 2026 ^[1]. Which pediatric sections were rewritten in this revision has not been reported.

The listed indications include reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, long-term weight reduction and maintenance, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults, under accelerated approval ^[1]. Combining Wegovy with another semaglutide-containing product or with any other GLP-1 receptor agonist is not recommended ^[1]. The most common adverse reactions, at an incidence of 5 percent or higher in adults or pediatric patients aged 12 years and older, are nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease and hair loss ^[1].

Why it matters for patients

The label is the document that prescribers, pharmacists and the Wegovy Medication Guide are built from, so language here reaches routine care ^[1]. A few items have direct practical consequences.

The anesthesia warning ties aspiration events in this drug class to elective surgeries and procedures, including those using deep sedation, which is why the label asks patients to tell providers about planned procedures ^[1]. The pregnancy instruction sets a defined window of at least two months off the drug before trying to conceive, for the cardiovascular risk reduction, weight reduction and certain MASH uses described in the label ^[1]. The breastfeeding statement in the highlights is written for Wegovy tablets; the highlights do not state a separate lactation recommendation for the injection ^[1].

The two contraindications define groups who should not receive the drug at all, and the pen-sharing warning applies to a single-patient-use device that delivers four 2.4 mg doses ^[1]. Nothing in the revised label changes the boxed warning on thyroid C-cell tumors, which remains in place ^[1].

The document does not list adverse reactions newly added in June 2026, and it does not state a reason for the removal of the suicidal behavior and ideation warning beyond the date listed ^[1].